Medical device

Setting A New Security Benchmark: Kudelski IoT's Semiconductor Alliances Redefine IoT Provisioning

Retrieved on: 
Wednesday, April 10, 2024
Control, Silicon Labs, Consumer electronics, Medical device, Connectivity Standards Alliance, Original equipment manufacturer, Internet of things, Library, Embedded, FOTA, Laboratory, Senior, Kudelski Group, Kudelski, Silicon, OEM, Home automation, Cloud computing, STMicroelectronics, Automation, PKI, Integrated circuit, Video game

Setting A New Security Benchmark: Kudelski IoT's Semiconductor Alliances Redefine IoT Provisioning

Key Points: 
  • Setting A New Security Benchmark: Kudelski IoT's Semiconductor Alliances Redefine IoT Provisioning
    Premier integration with Microchip, and collaborative partnerships with ST Microelectronics, Infineon, and Silicon Labs radically simplify a critical IoT security requirement.
  • Kudelski IoT libraries are integrated with semiconductor partner tools to enable device manufacturers to personalize their products in the factory or in the field.
  • Hardy Schmidbauer, Senior Vice President at Kudelski IoT, said, “For many IoT device manufacturers, security provisioning is today a laborious manual process that is prone to error, seriously compromising the security of individual devices, or even of a manufacturer’s whole chain of security.
  • By partnering with top IC manufacturers, Kudelski IoT is making provisioning a simpler, more automated, and secure process than ever before.

OnePlus AI Is Coming: Opening a New Era of AI-Driven, User-Centric Innovation

Retrieved on: 
Wednesday, April 10, 2024
OnePlus Nord, Environment, Intelligence, Pedestrian, AI, OnePlus, LLM, Love, Creativity, Data, Medical device

Powered by OnePlus' proprietary large language model, AI Eraser marks a revolutionary step forward in smartphone technology, liberating user productivity and creativity with more intuitive experiences.

Key Points: 
  • Powered by OnePlus' proprietary large language model, AI Eraser marks a revolutionary step forward in smartphone technology, liberating user productivity and creativity with more intuitive experiences.
  • "Empowering users with advanced, practical technology is what we live for at OnePlus," said Kinder Liu, President and COO of OnePlus.
  • "We believe that the potential for generative AI on mobile devices is enormous, with the power to completely transform productivity and creativity.
  • Starting from April, the feature will be rolled out gradually to OnePlus devices including the OnePlus 12, OnePlus 12R, OnePlus 11, OnePlus Open, and OnePlus Nord CE 4.

Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland

Retrieved on: 
Wednesday, April 10, 2024
Cloud, European Economic Area, MRI, CE, Partnership, Research, Science, Radiology, AI, Software, T-Systems, EEA, MDR, PACS, BSI Group, Health, BSI, Medical device

Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland.

Key Points: 
  • Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland.
  • T-Systems Switzerland, as a subsidiary of T-Systems International GmbH, is considered a system-relevant IT and digitalization partner in the healthcare sector in Switzerland.
  • Through this cooperation, T-Systems Switzerland distributes the AI-based solution for prostate analysis from FUSE-AI centrally in Switzerland, thereby enabling the commercialization of «Prostate.Carcinoma.ai» for radiological clinics and practices.
  • Xlife Sciences sees this partnership as a significant contribution to continuing its mission to bridge the gap between innovations and the needs of the healthcare market.

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Wednesday, April 10, 2024
Consensus, Glaucoma, Conditional sentence, University, Finance, RMB, Risk, Approximation error, Patient, Artificial intelligence, Medical device, National Health Commission, Optometry, Endocrinology, Dementia, Certification, Hyperthyroidism, Ageing, Capital Medical University, Software, MICCAI, Hypertensive retinopathy, Beijing Tongren Hospital, Neurology, Acceleration, Intelligence, Paratriathlon, Hospital, Research, Near-sightedness, Amblyopia, AI, MDR, Strabismus, Skin, AMD, Ranibizumab, Diagnosis, Peking University, Growth, Cardiology, Physical examination, News, Cataract, Diabetic retinopathy, Ophthalmology

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Retrieved on: 
Wednesday, April 10, 2024
Certification, Radiation, Prostate cancer, Prostate, Seed, Eye, MDR, Neoplasm, Way, Brachytherapy, Medical device regulation, Health, Medical device

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Key Points: 
  • Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
    The issuer is solely responsible for the content of this announcement.
  • This important milestone guarantees a high level of patient safety and the long-term availability of the seeds within the EU.
  • Prostate seeds have been manufactured and internationally marketed by Eckert & Ziegler since 1999 and contribute several million euros in annual sales to the Eckert & Ziegler Group's earnings.
  • This is not only a significant achievement for the distribution of our brachytherapy products, but for the entire Eckert & Ziegler Group," explained Katrin Antonenko, Managing Director of Eckert & Ziegler BEBIG GmbH.

Dalata Hotel Group PLC: TVR-Total Voting Rights

Retrieved on: 
Wednesday, April 10, 2024
Dalata Hotel Group, Medical device

In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, Dalata Hotel Group plc announces that:

Key Points: 
  • In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, Dalata Hotel Group plc announces that:
    As of 2 April 2024, Dalata Hotel Group plc’s share capital consists of 224,261,937 Ordinary Shares of nominal value €0.01 each.
  • Dalata Hotel Group plc does not hold any Ordinary Shares in treasury.
  • Therefore, the total number of voting rights in Dalata Hotel Group plc is 224,261,937.
  • The above figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Dalata Hotel Group plc under the Transparency (Directive 2004/109/EC) Regulations 2007.

EQS-News: STAIDIUM U.S. to demonstrate its KI-powered Streaming-Technology at a MLS NEXT PRO match

Retrieved on: 
Wednesday, April 10, 2024
Major League Soccer, Inter Miami CF, Generation Adidas Cup, U-17, Inter Miami CF II, OTT, Artificial intelligence, MLS, MLS Next Pro, League, Medical device

The MLS NEXT PRO regular season match will be streamed live by STAIDIUM U.S.’ fully automated and AI-based camera system as part of the MLS Innovation Lab program.

Key Points: 
  • The MLS NEXT PRO regular season match will be streamed live by STAIDIUM U.S.’ fully automated and AI-based camera system as part of the MLS Innovation Lab program.
  • DALLAS (March 28, 2024) – STAIDIUM U.S., a leader in using artificial intelligence (AI) to deliver automated sports streaming, has announced that it will stream the regular season match Orlando City B vs. Inter Miami II of MLS NEXT PRO.
  • The match will be hosted at the 2024 Generation adidas Cup, the premier international youth soccer tournament hosted by Major League Soccer and MLS NEXT.
  • As part of the recently-launched MLS Innovation Lab , MLS NEXT Pro will partner with STAIDIUM U.S. to trial their AI-powered and 5G-enabled camera to offer live streams and automated broadcast productions of season matches.

EQS-News: AI specialist strengthens INDUS portfolio

Retrieved on: 
Wednesday, April 10, 2024
Automation, Assembly, Growth, Artificial intelligence, Acquisition, Robotics, AI, Engineering, SDAX, Herman Kelly and Life, Medical device

Bergisch Gladbach, 14 March 2024 – SDAX-listed investment company INDUS Holding AG has acquired Gestalt Robotics.

Key Points: 
  • Bergisch Gladbach, 14 March 2024 – SDAX-listed investment company INDUS Holding AG has acquired Gestalt Robotics.
  • Its portfolio of solutions comprises image processing and control technology based on artificial intelligence.
  • The acquisition thus supports our strategic initiative ‘Driving innovation’, which, among other things, promotes the rapid implementation of AI solutions in our portfolio companies.”
    Thomas Staufenbiel and Prof. Dr.-Ing.
  • “Gestalt Robotics’ focus on industrial automation complements our investment portfolio in the Engineering segment very well,” says Axel Meyer, Board member of INDUS Holding AG responsible for the Engineering segment.

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on: 
Wednesday, April 10, 2024
Tsinghua University, OCTA, Alzheimer's disease, Finance, CE, Patient, Artificial intelligence, Adolescence, World's fair, Medical device regulation, Dementia, CNV, Certification, Hyperthyroidism, HK, Partnership, Policy, MICCAI, Safety, Lighting, Optical coherence tomography angiography, Intelligence, Choroidal neovascularization, Journal, Hospital, Research, Near-sightedness, Amblyopia, AI, Insurance, Strabismus, AMD, Gold medal, Diagnosis, Peking University, Conference, Growth, Biomarker, Plaque, News, Bleeding, Google Images, Rehabilitation, Medical device

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points: 
  • Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
    On March 27, medical artificial intelligence company Airdoc Technology (2251.
  • In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
  • In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
  • In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.

EQS-News: Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Wednesday, April 10, 2024
CE, Asos, Drug discovery, Central nervous system, Patient, Ophthalmology, RNA, Research, CBO, Protein, Drug development, Medical device

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG

Key Points: 
  • EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Dallas, TX, USA and Martinsried, Germany, March 20, 2024 – Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.